Actively Recruiting
The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for Gastric Cancer
Led by Chinese University of Hong Kong · Updated on 2026-04-08
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Gastric cancer is a leading cause of cancer-related deaths globally. For patients with resectable gastric cancer, surgery to remove the stomach (gastrectomy) combined with chemotherapy improves survival. Minimally invasive gastrectomy (MIG) is increasingly used to reduce surgical trauma while maintaining effective cancer treatment. However, MIG has technical challenges, such as limited instrument movement and depth perception. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) may overcome these challenges by providing enhanced dexterity, 3D visualization, and precise control to improve surgical accuracy. This observational study aims to create an international registry to monitor RAMIG techniques and outcomes worldwide and to understand the learning curve for surgeons adopting RAMIG. The study collects data both prospectively and retrospectively from patients undergoing RAMIG for gastric cancer across multiple continents through the Upper Gastrointestinal International Robotic Association (UGIRA). The registry gathers detailed information on surgical techniques, postoperative outcomes, and complications using standardized definitions. This approach enables consistent comparison of results globally. The study also supports surgeons in training by evaluating their progress during the learning phase of RAMIG, aiming to reduce complications and improve patient safety during this period. Participants in this study are patients with gastric cancer scheduled for RAMIG. Data collected include operation time, blood loss, complications during surgery, conversion rates to open surgery, completeness of tumor removal, and number of lymph nodes removed. Postoperative adverse events are tracked up to 90 days after surgery. By collecting uniform data through an online system, the study aims to provide insights into surgical quality and outcomes while monitoring the learning curve for this advanced robotic technique. The study will continue through 2031, supporting international collaboration and quality improvement in robotic gastrectomy.
CONDITIONS
Brief Title
The UGIRA International Registry for RAMIG for Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All gastric cancer patients undergoing Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) in a participating center
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of surgery and hospital stay post-surgery
Participants undergo Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) followed by immediate post-operative care.
1 surgical procedure and hospital stay
Duration - Up to 90 days after surgery
Participants are monitored for adverse events and surgical outcomes after surgery.
Approximately 2 to 3 follow-up visits within 90 days post-surgery
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong, Shatin, HK
Hong Kong, Hong Kong
Actively Recruiting
Research Team
S
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery)
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here